{
    "code": 0,
    "data": [
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b332abaf-4a18-469a-b82a-c8e187b841ec.pdf",
            "news_date": "2026-02-11 13:58:06"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ajay Patel",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3BB90179_A09E_48CD_8602_80B8CF579FD1_173719.pdf",
            "news_date": "2026-02-09 17:37:28"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ajay Mansukhlal Patel HUF",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=CA00819D_E0D4_4B40_9112_5FA840C7AE9B_173510.pdf",
            "news_date": "2026-02-09 17:35:14"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General",
            "descriptor": "General",
            "caption": "Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ajay Mansukhlal Patel & PACs",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0DD676C8_01D2_4E61_BA62_A7B7CBFFE85C_173325.pdf",
            "news_date": "2026-02-09 17:33:32"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Filing Of Report Under Regulation 7(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015 As Amended (SEBI Insider Trading Regulations)",
            "news_body": "Enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7cf3a0a-efc2-480b-9d02-dbc6669a3efa.pdf",
            "news_date": "2026-02-09 17:11:05"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Reg. 2011",
            "caption": "Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ajay Patel",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3C99B2B2_B3E6_47C2_AC91_5AFA81489630_153230.pdf",
            "news_date": "2026-01-29 15:32:35"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 21 January 2026 post announcement of the financial results of the Company for the quarter and nine months ended 31 December 2025.",
            "news_id": "7db48c03-3170-415a-8aa9-9bfdeb4a9443",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98590399-a1e5-4850-b1d1-7dc5a0e0624c.pdf",
            "news_date": "2026-01-24 11:19:07",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 21 January 2026 post announcement of the financial results of the Company for the quarter and nine months ended 31 December 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98590399-a1e5-4850-b1d1-7dc5a0e0624c.pdf",
            "news_date": "2026-01-24 11:19:07"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Nine Months ended 31 December 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8414cf66-09f6-4c24-b414-c2fa4e313756.pdf",
            "news_date": "2026-01-22 10:37:49"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earning call held on Wednesday 21 January 2026 at 05:00 p.m. (IST) is attached.",
            "news_id": "33afea00-37eb-4dc6-8383-f7b57bc891f9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=006d77e4-a46d-437f-bea4-75bf9ebf9b33.pdf",
            "news_date": "2026-01-21 18:54:57",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earning call held on Wednesday 21 January 2026 at 05:00 p.m. (IST) is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=006d77e4-a46d-437f-bea4-75bf9ebf9b33.pdf",
            "news_date": "2026-01-21 18:54:57"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months ended 31 December 2025.",
            "news_id": "bb7dc070-45e2-4b01-8b26-e349eb2ba63f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f2c09b5-05e5-4855-a958-c87b55f93e94.pdf",
            "news_date": "2026-01-21 16:10:10",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months ended 31 December 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f2c09b5-05e5-4855-a958-c87b55f93e94.pdf",
            "news_date": "2026-01-21 16:10:10"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 21.01.2026",
            "news_body": "Outcome of the Board Meeting held on 21.01.2026",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3712cb12-772f-43ef-be74-ffefa4c84744.pdf",
            "news_date": "2026-01-21 16:01:48"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2025",
            "news_body": "Enclosed",
            "news_id": "1eeae038-3dd2-42bc-b39b-086093168d2e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7675a64a-847f-4adc-932a-352bb723d809.pdf",
            "news_date": "2026-01-21 15:56:08",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2025",
            "news_body": "Enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7675a64a-847f-4adc-932a-352bb723d809.pdf",
            "news_date": "2026-01-21 15:56:08"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and nine months ended 31 December 2025 is scheduled on Wednesday 21 January 2026 at 05:00 p.m. (IST).\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19085d6a-9431-4c32-86b3-dad61ec3641a.pdf",
            "news_date": "2026-01-12 14:31:00"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday 21.01.2026",
            "news_body": "Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2026 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2025.\r\n\r\nFurther in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2026 till the expiry of 48 hours from the date the said financial results are made public.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a4760f4-c11f-41f9-8a97-7864ff7990da.pdf",
            "news_date": "2026-01-12 14:12:34"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0dced1b-ef75-4b6c-9bc1-cc7e1e01b114.pdf",
            "news_date": "2026-01-08 12:06:50"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=76e77e01-b349-4d8d-9c0d-d768b862bd67.pdf",
            "news_date": "2025-12-26 11:35:57"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b8cd3e5-dae0-4b75-981a-83bd65cfd2bc.pdf",
            "news_date": "2025-11-22 11:03:24"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2db50a35-c6bb-4ce2-91ca-3526cfe10aab.pdf",
            "news_date": "2025-11-15 13:59:31"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=859fa4fb-3ac6-46b0-89ec-eca0a8b00b49.pdf",
            "news_date": "2025-11-11 11:07:58"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91836996-daa6-49e8-9fc4-d0b455e0f8f3.pdf",
            "news_date": "2025-11-07 12:02:55"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b392a177-3487-4166-aba7-9417dc1216dc.pdf",
            "news_date": "2025-11-07 11:57:57"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6fa1329d-e4ef-49da-a68d-3b96b8fac6f9.pdf",
            "news_date": "2025-11-07 11:53:14"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92c64702-7d8c-43d6-89ee-f5e6ba6178db.pdf",
            "news_date": "2025-11-06 16:34:06"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=96166b74-f796-43a3-983b-116f703f7db2.pdf",
            "news_date": "2025-11-05 14:00:53"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 31 October 2025 post announcement of the financial results of the Company for the quarter and half year ended 30 September 2025.",
            "news_id": "45315886-4a96-406e-8a7c-ff65b40310f3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1dff5871-12db-4395-b8d6-48b90f2bf81f.pdf",
            "news_date": "2025-11-04 12:16:44",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 31 October 2025 post announcement of the financial results of the Company for the quarter and half year ended 30 September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1dff5871-12db-4395-b8d6-48b90f2bf81f.pdf",
            "news_date": "2025-11-04 12:16:44"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Extract of Financial Results of the Company for the quarter and half year ended 30 September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eea0e450-beaf-44f7-915b-2502171a6c8c.pdf",
            "news_date": "2025-11-01 11:38:25"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Friday 31 October 2025 at 05:00 p.m. (IST) is attached.",
            "news_id": "5ab90549-4234-49d5-a93f-a438e8028e71",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac3b457a-903c-4955-91bc-207a06c18e1b.pdf",
            "news_date": "2025-10-31 19:18:49",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Friday 31 October 2025 at 05:00 p.m. (IST) is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac3b457a-903c-4955-91bc-207a06c18e1b.pdf",
            "news_date": "2025-10-31 19:18:49"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and half year ended 30 September 2025.",
            "news_id": "e8ef3ff1-3ee9-4cc9-a644-261f5b2d9770",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c5075fa5-d0b9-4bec-bb4d-be981ed10d47.pdf",
            "news_date": "2025-10-31 16:06:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and half year ended 30 September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c5075fa5-d0b9-4bec-bb4d-be981ed10d47.pdf",
            "news_date": "2025-10-31 16:06:36"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India (\"SEBI\") (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "Detailed disclosure is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3cf9412-f85d-4495-8384-530488096f58.pdf",
            "news_date": "2025-10-31 15:55:58"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Detailed disclosure is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d18e8c4a-6dbc-4f85-9b3f-6233a6b227cd.pdf",
            "news_date": "2025-10-31 15:52:12"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 31.10.2025",
            "news_body": "Outcome Of the Board Meeting Held On 31.10.2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0634d5d6-cfc9-4a00-a904-981c478641a5.pdf",
            "news_date": "2025-10-31 15:49:30"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2025",
            "news_body": "Enclosed",
            "news_id": "5120ca5b-c61d-4678-b0b4-911b5618cb91",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1340d64-38d9-4e7b-803b-f5898aa60b87.pdf",
            "news_date": "2025-10-31 15:45:06",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2025",
            "news_body": "Enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1340d64-38d9-4e7b-803b-f5898aa60b87.pdf",
            "news_date": "2025-10-31 15:45:06"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Price Movement",
            "news_body": "Clarification on Price Movement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38d9f1d3-4a20-44eb-aa49-ee2e84609dbf.pdf",
            "news_date": "2025-10-24 10:53:38"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification Sought from Tatva Chintan Pharma Chem Ltd",
            "news_body": "The Exchange has sought clarification from Tatva Chintan Pharma Chem Ltd on October 23 2025 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.",
            "file_url": "",
            "news_date": "2025-10-23 17:44:03"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and half year ended 30 September 2025 is scheduled on Friday 31 October 2025 at 05:00 p.m. (IST).\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.\r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df5f940a-73bd-4a5d-8522-63f32fe67836.pdf",
            "news_date": "2025-10-17 20:51:14"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday 31.10.2025",
            "news_body": "Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2025.\r\n\r\nFurther in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 October 2025 till the expiry of 48 hours from the date the said financial results are made public.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21f0364e-1589-4330-83e5-4b1b4ebce5ea.pdf",
            "news_date": "2025-10-17 20:31:27"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=206c80f3-1903-4730-a4e7-43f2923d51c7.pdf",
            "news_date": "2025-10-06 17:18:52"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
            "news_body": "Scrutinizers Report / Voting Results of 29th Annual General Meeting of the Company held on Friday 26 September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8bd4551f-0d06-478b-b0ac-1fc9da20033e.pdf",
            "news_date": "2025-09-27 17:47:59"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Summary of proceedings of the 29th Annual General Meeting held on Friday 26 September 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3097df68-3896-479d-b7e9-1ece8f5ce4e6.pdf",
            "news_date": "2025-09-26 19:14:20"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=35292f1c-f7bf-4f87-a354-5c13e2e5b486.pdf",
            "news_date": "2025-09-25 17:38:10"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f7bedd8-a396-434e-87de-c863c3ce2c8d.pdf",
            "news_date": "2025-09-04 19:27:15"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99c5f6db-d101-4802-8e53-e8f807f0738b.pdf",
            "news_date": "2025-09-04 19:22:49"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9eb93f9-f961-4d34-a57a-d4024cee2946.pdf",
            "news_date": "2025-09-01 13:51:34"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Advertisement - Disclosure under Regulation 30 44 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended. (\"SEBI Listing Regulations\") - (Post Dispatch)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d56bdca-a431-47cf-9d87-2477d8fb9db8.pdf",
            "news_date": "2025-08-27 11:32:53"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Intimation Of Record Date Book Closure And Cut-Off Date Pursuant To Regulation 42 And 44 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)",
            "news_body": "Intimation of Record Date Book Closure and Cut-Off Date pursuant to Regulation 42 and 44 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31f44f13-0833-422a-9a80-29e66f35597a.pdf",
            "news_date": "2025-08-26 17:31:51"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Business Responsibility and Sustainability Reporting (BRSR)",
            "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
            "news_body": "Pursuant to Regulation 34(2)(f) of the SEBI Listing Regulations we are submitting herewith the Business Responsibility and Sustainability Report (\"BRSR\") for FY 2024-25 which forms part of the Annual Report FY 2024-25.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fea4dc6-9c8c-471f-9b80-c24998ac94e5.pdf",
            "news_date": "2025-08-26 17:10:02"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "Pursuant to Regulation 34(1) of the SEBI Listing Regulations please find enclosed herewith the Annual Report of the Company along with the Notice of the 29th Annual General Meeting (AGM) and other Statutory Reports for the Financial Year 2024-25. The same is also being sent through electronic mode to those members whose email addresses are registered with the Company / Registrar and Share Transfer Agent (RTA) / Depositories. Further pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations a letter containing the web-link along with the exact path for accessing the Annual Report is being sent to those Members whose email addresses are not registered with the Company / RTA / Depositories. \r\n\r\nFurther the 29th AGM of the Company will be held on Friday 26 September 2025 at 04:00 p.m. (IST) through Video Conferencing (\"VC\") / Other Audio Visual Means (\"OAVM\"). \r\n\r\nThe Annual Report of the Company is also available on the website of the Company at www.tatvachintan.com.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bbd94785-2fd6-4756-8098-d33b706637a8.pdf",
            "news_date": "2025-08-26 16:57:18"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "AGM",
            "caption": "Notice Of The 29Th AGM Of The Members Of The Company Scheduled To Be Held On Friday 26 September 2025 At 04:00 P.M. (IST) Through Video Conferencing (\"VC\") / Other Audio Visual Means (\"OAVM\")",
            "news_body": "Notice of the 29th AGM of the Members of the Company scheduled to be held on Friday 26 September 2025 at 04:00 p.m. (IST) through Video Conferencing (\"VC\") / Other Audio Visual Means (\"OAVM\")",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=628a0cea-3244-40b5-b166-0f7198932b62.pdf",
            "news_date": "2025-08-26 16:44:09"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication regarding \"100 days Campaign - Saksham Niveshak\"",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8bd1ae94-618e-4107-9e4d-fb4f968f7438.pdf",
            "news_date": "2025-08-20 11:05:05"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Advertisement - Disclosure under Regulation 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended. (\"SEBI Listing Regulations\") - (Pre Dispatch)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99626019-ff9b-4b5e-ad34-7722be2278c8.pdf",
            "news_date": "2025-08-19 13:23:44"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c43596e0-b1ab-4056-882c-1b9158eb6b4c.pdf",
            "news_date": "2025-08-12 15:46:48"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Communication To Shareholders - Dividend For FY 2024-25 - Intimation On Tax Deduction At Source (TDS) / Withholding Tax On Dividend",
            "news_body": "Communication to Shareholders - Dividend for FY 2024-25 - Intimation on Tax Deduction at source (TDS) / withholding tax on Dividend",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3199ed1-9c17-4a35-8f73-1d90372535e1.pdf",
            "news_date": "2025-08-12 15:37:46"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42b7246a-2525-405b-b437-9b3add2c83f6.pdf",
            "news_date": "2025-08-11 17:25:06"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 24 July 2025 post announcement of financial results of the Company for the quarter ended 30 June 2025.",
            "news_id": "0512a727-f2d4-4085-92e1-c16a96d7a6cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21cafcb0-5a4b-41bc-8bbd-d22bc1fe6a70.pdf",
            "news_date": "2025-07-28 14:49:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 24 July 2025 post announcement of financial results of the Company for the quarter ended 30 June 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21cafcb0-5a4b-41bc-8bbd-d22bc1fe6a70.pdf",
            "news_date": "2025-07-28 14:49:39"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Extract of Financial Results of the Company for the quarter ended 30 June 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=75c82ddb-cea5-4ca9-a818-49cd0885f161.pdf",
            "news_date": "2025-07-25 14:11:26"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Thursday 24 July 2025 at 05:00 p.m. (IST) is attached.",
            "news_id": "a1333e37-84e1-496d-870e-efb4f0d89160",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f802fc6-0fbb-4f42-8114-ca6c7452f35f.pdf",
            "news_date": "2025-07-24 19:09:41",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Thursday 24 July 2025 at 05:00 p.m. (IST) is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f802fc6-0fbb-4f42-8114-ca6c7452f35f.pdf",
            "news_date": "2025-07-24 19:09:41"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30 June 2025.",
            "news_id": "0e61fd3e-b78f-4101-94b0-8173bc56b5e8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=24014063-8902-49ca-9450-f324d81a0a06.pdf",
            "news_date": "2025-07-24 15:57:27",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30 June 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=24014063-8902-49ca-9450-f324d81a0a06.pdf",
            "news_date": "2025-07-24 15:57:27"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Resignation of Chief Financial Officer (CFO)",
            "caption": "Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)",
            "news_body": "Detailed disclosure is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbce6183-9487-41ae-95a1-9a195c991494.pdf",
            "news_date": "2025-07-24 15:50:16"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "Detailed disclosure is enclosed.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f52afd41-5be0-40c6-aa51-3473b758fd9d.pdf",
            "news_date": "2025-07-24 15:47:27"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 24.07.2025",
            "news_body": "Outcome Of The Board Meeting Held On 24.07.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c775d26-a1cd-4ed3-9fb1-e6814bfc5b85.pdf",
            "news_date": "2025-07-24 15:44:55"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30 June 2025",
            "news_body": "Enclosed",
            "news_id": "8efd88ea-304a-4c84-b469-0786fdf9f565",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7749674a-c617-494e-b16a-b1d19a155fd8.pdf",
            "news_date": "2025-07-24 15:40:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30 June 2025",
            "news_body": "Enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7749674a-c617-494e-b16a-b1d19a155fd8.pdf",
            "news_date": "2025-07-24 15:40:26"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter ended 30 June 2025 is scheduled on Thursday 24 July 2025 at 05:00 p.m. (IST).\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ebe1258-1825-42f8-ae6a-8f03e485df0b.pdf",
            "news_date": "2025-07-17 18:33:11"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday 24.07.2025",
            "news_body": "Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2025.\r\n\r\nFurther in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 July 2025 till the expiry of 48 hours from the date the said financial results are made public.\r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98883323-2a3a-4086-9788-4a95e6c7c277.pdf",
            "news_date": "2025-07-17 17:50:06"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nippon India Mutual Fund",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=994A64AD_588E_413D_BC9C_DEF90A50ACCE_172746.pdf",
            "news_date": "2025-07-07 17:27:51"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=499a9854-6ebb-49eb-b110-4ac7b572d507.pdf",
            "news_date": "2025-07-05 14:37:58"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0726e7a-2300-4e79-b398-bc72d016012b.pdf",
            "news_date": "2025-06-25 12:08:33"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Credit Rating",
            "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
            "news_body": "Intimation of Credit Rating",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0c58a47-d26d-40cb-bf77-0c489fdc6807.pdf",
            "news_date": "2025-06-17 17:44:16"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Price Movement",
            "news_body": "Clarification on Price Movement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f257c5f-644f-41db-8ce2-8eeff37a263c.pdf",
            "news_date": "2025-05-23 10:08:25"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General",
            "descriptor": "Clarification",
            "caption": "Clarification sought from Tatva Chintan Pharma Chem Ltd",
            "news_body": "The Exchange has sought clarification from Tatva Chintan Pharma Chem Ltd on May 22 2025 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.<BR>",
            "file_url": "",
            "news_date": "2025-05-22 18:45:40"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Increase / Spurt In Volume",
            "news_body": "Clarification on Increase / Spurt in Volume",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4246a4ff-1616-4f1c-a11d-1b87eae68abc.pdf",
            "news_date": "2025-05-21 12:18:09"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Compliance",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "Submission of Annual Secretarial Compliance Report for the financial year ended 31 March 2025 (2024-25).",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=13809334-ec1e-4b96-83b1-48f0e63ffb5e.pdf",
            "news_date": "2025-05-14 17:22:33"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 05 May 2025 post announcement of the financial results of the Company for the quarter and financial year ended 31 March 2025.",
            "news_id": "17eca8ae-578a-49f1-bde3-466f6a5e9bd0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aeb51fdb-77f9-4e5c-89d8-33753d794828.pdf",
            "news_date": "2025-05-09 16:25:03",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 05 May 2025 post announcement of the financial results of the Company for the quarter and financial year ended 31 March 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aeb51fdb-77f9-4e5c-89d8-33753d794828.pdf",
            "news_date": "2025-05-09 16:25:03"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earning call held on Monday 05 May 2025 at 05:00 p.m. (IST) is attached.",
            "news_id": "e98923f4-bf5d-46ed-8c5e-f2772d6b3c1f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59b96c3f-9d2c-461a-ae96-65c3ef70fbd8.pdf",
            "news_date": "2025-05-05 19:16:55",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earning call held on Monday 05 May 2025 at 05:00 p.m. (IST) is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59b96c3f-9d2c-461a-ae96-65c3ef70fbd8.pdf",
            "news_date": "2025-05-05 19:16:55"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and financial year ended 31 March 2025.",
            "news_id": "387174d8-b512-4c66-bfdd-971dacc7ec9c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f7aae476-4c32-4e70-a456-8fb82cdd7450.pdf",
            "news_date": "2025-05-05 14:58:15",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter and financial year ended 31 March 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f7aae476-4c32-4e70-a456-8fb82cdd7450.pdf",
            "news_date": "2025-05-05 14:58:15"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Award of Order / Receipt of Order",
            "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
            "news_body": "Announcement under Regulation 30 (LODR) - Receipt of Order",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a77818bb-ca39-48cc-8882-4120d5f5cdac.pdf",
            "news_date": "2025-05-05 14:51:26"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Financial Year Ended 31 March 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0904ecd-a1ed-489b-ac80-2140f2f3c8b4.pdf",
            "news_date": "2025-05-03 14:40:19"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2025",
            "news_body": "Enclosed",
            "news_id": "14a53d54-1cbb-4b11-b5e3-54419e3aac9e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f2c0537-e8fa-44c5-8b21-424ab5af8d30.pdf",
            "news_date": "2025-05-02 17:20:19",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2025",
            "news_body": "Enclosed",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f2c0537-e8fa-44c5-8b21-424ab5af8d30.pdf",
            "news_date": "2025-05-02 17:20:19"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Appointment Of Secretarial Auditor Cost Auditor And Internal Auditor",
            "news_body": "Appointment of Secretarial Auditor Cost Auditor and Internal Auditor",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=adc555a6-775b-4b07-97ef-f5b3b7f19191.pdf",
            "news_date": "2025-05-02 17:13:19"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Dividend Updates",
            "caption": "Announcement under Regulation 30 (LODR)-Dividend Updates",
            "news_body": "Outcome of Board Meeting - Board approves Dividend",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0cc05fab-d36d-436c-aaf8-6e827be62163.pdf",
            "news_date": "2025-05-02 17:10:01"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "Outcome of Board Meeting - Board approves Dividend",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d41ba378-29a8-4000-b5a2-4ff08190db38.pdf",
            "news_date": "2025-05-02 17:07:56"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 02.05.2025",
            "news_body": "Outcome of the Board Meeting held on 02.05.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9faf0b2-4f1a-4d2f-97a6-0eefe1dfb057.pdf",
            "news_date": "2025-05-02 16:59:37"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Compliance",
            "descriptor": "Format of the Annual Disclosure to be made by an entity identified as a LC : Annexure B2",
            "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2",
            "news_body": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px>    <tr>       <td><b>Sr. No.</b></td>       <td><b>Particulars</b></td>       <td><b>Details</b></td>    </tr>    <tr>       <td>1</td>       <td>Name of Company</td>       <td>Tatva Chintan Pharma Chem Ltd</td>    </tr>    <tr>       <td>2</td>       <td>CIN NO.</td>       <td>L24232GJ1996PLC029894</td>    </tr>    <tr>       <td>3</td>       <td>Report filed for FY</td>       <td>2024-2025</td>    </tr>       <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr>       <td>4</td>       <td>2 - year block period (Specify financial years)* </td>       <td>FY 2024-25 and FY 2025-26</td>    </tr>    <tr>    <tr>       <td>5</td>       <td>Incremental borrowing done in FY (T)(a) </td>       <td>0.00</td>    </tr>    <tr>       <td>6</td>       <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td>       <td>0.00</td>    </tr>    <tr>       <td>7</td>       <td>Actual borrowing done through debt securities in FY (T)(c)</td>       <td>0.00</td>    </tr>       <tr>       <td>8</td>       <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td>       <td>0</td>    </tr>  <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td>       <td>0</td>    </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td>       <td>0</td>    </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>FY 2023-24 and FY 2024-25</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div>     <br/><br/><br/>    <table><tr><td>Name of the Company Secretary :-</td><td>Ishwar Nayi</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr>    <tr><td>Name of the Chief Financial Officer :- </td><td>Ashok Bothra</td></tr>    <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 29/04/2025<br/><br/></div>",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=676b4f28-473b-4f07-aaa7-63e6d0ad641c.pdf",
            "news_date": "2025-04-29 14:42:28"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Compliance",
            "descriptor": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure ",
            "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
            "news_body": "  <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Tatva Chintan Pharma Chem Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24232GJ1996PLC029894</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.64</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>A-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>CRISIL LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table>  <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Ishwar Nayi <br/>  Designation: Company Secretary and Compliance Officer <br/> EmailId: cs@tatvachintan.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Ashok Bothra <br/> Designation: Chief Financial Officer <br/> EmailId: finance@tatvachintan.com</div> </div> <div> <br/> Date: 29/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23349a78-e866-4a03-8773-dbe0ea6e198f.pdf",
            "news_date": "2025-04-29 14:23:09"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "In continuation of our earlier announcement dated 25 April 2025 we would like to inform that the Earnings Call post announcement of financial results of the Company for the quarter and financial year ended 31 March 2025 which was scheduled to be held on Friday 02 May 2025 at 05:00 p.m. IST has been rescheduled on Monday 05 May 2025 at 05:00 p.m. IST.\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46f4a3a0-07ee-4f46-947d-1fd94c943268.pdf",
            "news_date": "2025-04-28 15:59:52"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and financial year ended  31 March 2025 is scheduled on Friday 02 May 2025 at 05:00 p.m. IST.\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec96772c-cb69-44f5-bada-98c3f9c1d6f6.pdf",
            "news_date": "2025-04-25 17:43:29"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Board Meeting Intimation For Intimation Of Board Meeting To Be Held On Friday 02.05.2025",
            "news_body": "Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2025 inter alia to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2025;\r\n\r\n2. consider and recommend a final dividend if any on the equity shares of the Company for the financial year ended 31 March 2025 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.\r\n\r\nFurther in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 April 2025 till the expiry of 48 hours from the date the said financial results are made public.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6484e611-987d-4cee-b362-0bafdf251323.pdf",
            "news_date": "2025-04-25 17:27:30"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Of Change In Contact Details Of MUFG Intime India Private Limited Registrar And Share Transfer Agent (RTA) Of The Company.",
            "news_body": "Intimation of change in contact details of MUFG Intime India Private Limited Registrar and share Transfer Agent (\"RTA\") of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2bd222e-d238-4a2d-aabd-8bc7aa6cc9fa.pdf",
            "news_date": "2025-04-19 15:39:25"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6c7ee0e-01bd-4b63-b6f6-424c078c2761.pdf",
            "news_date": "2025-04-03 16:42:59"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7ff3c8d-dcc5-4461-bbfb-2723d41ce574.pdf",
            "news_date": "2025-03-26 09:59:03"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=091c7d49-4488-4a5b-a73b-13756b9b3df3.pdf",
            "news_date": "2025-03-24 10:26:32"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1d65222-928e-41d9-acaa-5db370738f8a.pdf",
            "news_date": "2025-03-18 13:46:56"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 28 January 2025 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2024.",
            "news_id": "66864f20-649f-485d-846f-fea9c0ff7417",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b42327e-9a70-445f-8a49-f9bd860d1944.pdf",
            "news_date": "2025-01-31 14:54:08",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 28 January 2025 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b42327e-9a70-445f-8a49-f9bd860d1944.pdf",
            "news_date": "2025-01-31 14:54:08"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Nine Months ended 31 December 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d095422b-2ad2-4b21-be65-401c3c5088db.pdf",
            "news_date": "2025-01-29 13:39:31"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earning call held on Tuesday 28 January 2025 at 05:00 p.m. (IST) is attached.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ce9cce0-d9f4-46dd-bc80-d06b5a81fe8c.pdf",
            "news_date": "2025-01-28 18:59:41"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Integrated Filing (Financial)",
            "caption": "Integrated Filing (Financial)",
            "news_body": "Integrated Filing (Financial) for the quarter and nine months ended 31 December 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf23b490-7476-4c71-a2c6-d23a7a349e5c.pdf",
            "news_date": "2025-01-28 16:15:10"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months ended 31 December 2024.",
            "news_id": "ddc36c61-338e-4907-aabc-291a67de2aa6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ead540b7-c2c2-44bd-ba12-1f89811376a2.pdf",
            "news_date": "2025-01-28 16:01:46",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months ended 31 December 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ead540b7-c2c2-44bd-ba12-1f89811376a2.pdf",
            "news_date": "2025-01-28 16:01:46"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 28.01.2025",
            "news_body": "Outcome of the Board Meeting held on 28.01.2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c0691c2-8c9e-406c-b3e7-5a2cb04e0e1f.pdf",
            "news_date": "2025-01-28 15:51:48"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2024",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31 December 2024",
            "news_id": "b2d27463-8814-465e-8611-2c09de9237fc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc3f2266-5e11-411b-a1a1-06ad22e93223.pdf",
            "news_date": "2025-01-28 15:45:15",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2024",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31 December 2024",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc3f2266-5e11-411b-a1a1-06ad22e93223.pdf",
            "news_date": "2025-01-28 15:45:15"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and nine months ended 31 December 2024 is scheduled on Tuesday 28 January 2025 at 05:00 p.m. (IST).\r\n\r\nThe Call is hosted by ICICI Securities and an invite in this regard is attached for your information and records.\r\n\r\nThe above information is also being made available on the website of the Company at https://www.tatvachintan.com/.\r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e49c0d64-7455-4a54-910c-4ccd71415303.pdf",
            "news_date": "2025-01-17 12:00:59"
        },
        {
            "co_code": 75545,
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Tuesday 28.01.2025",
            "news_body": "Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2024.\r\n\r\nFurther in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2025 till the expiry of 48 hours from the date the said financial results are made public.\r\n\r\nThe above information is also being made available on the website of the Company at www.tatvachintan.com.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c353a451-7260-4194-b347-7e2bc3a560e6.pdf",
            "news_date": "2025-01-17 11:39:36"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 25 October 2024 post announcement of financial results of the Company for the quarter and half year ended 30 September 2024.",
            "news_id": "bf8f4067-c9aa-4f3f-925f-7f645a043af4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82d3233f-799f-430e-81f8-75f2f6a8fb2b.pdf",
            "news_date": "2024-10-30 14:10:16",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Friday, 25 October 2024 at 05:00 p.m. (IST) is attached.",
            "news_id": "a6a92a73-3821-4c74-bf12-813bd1d4b397",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8976706a-e3e0-43ce-9a3b-876c83a0ea05.pdf",
            "news_date": "2024-10-25 20:33:09",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Half Year ended 30 September 2024.",
            "news_id": "b399a638-9270-43c6-8798-7d6251afe64f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=230952b7-2976-435e-8b10-cc610808a8c8.pdf",
            "news_date": "2024-10-25 16:06:25",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2024",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2024",
            "news_id": "a46a06fd-ac20-49e2-89b2-f132963f0da4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=034efd0b-f963-450b-a938-7130f80a854e.pdf",
            "news_date": "2024-10-25 15:50:21",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 24 July 2024 post announcement  of  financial results of the Company for the quarter ended 30 June 2024.",
            "news_id": "38c564ab-ecf3-43bd-8cb1-81aab252241c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d862cdf-2532-4ea7-bb38-1be24d65743b.pdf",
            "news_date": "2024-07-29 19:17:45",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Link of Audio Recording of the Earnings call held on Wednesday, 24 July 2024 at 05:00 p.m. (IST) is attached.",
            "news_id": "c340c9fa-926d-4983-b011-fe36f41a9321",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5793c877-1bd2-4564-8840-811565e86090.pdf",
            "news_date": "2024-07-24 20:32:49",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30 June 2024.",
            "news_id": "93256770-3887-4085-a4f1-a3c7ba3cd630",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=13a8e931-efb7-4c89-94a8-3aeb6d0d6ccd.pdf",
            "news_date": "2024-07-24 15:56:42",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On 30 June 2024.",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on 30 June 2024.",
            "news_id": "6fae59b0-b996-41c8-9154-868f07c7341b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7bc30181-f7ca-456e-a04d-cc6b0b66b8d9.pdf",
            "news_date": "2024-07-24 15:39:55",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 03 May 2024 post announcement of the financial results of the Company for the quarter and financial  year ended 31 March 2024.",
            "news_id": "237797da-6cca-487f-adcd-433501aaddec",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e715b9d7-9e22-45cc-8083-6f98413e2d3a.pdf",
            "news_date": "2024-05-07 12:50:56",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor  Presentation for the quarter and financial year ended 31 March 2024.",
            "news_id": "d783112e-dc82-4f77-8126-98c5866dfdd3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25ccc1b3-d263-4754-ac58-9db7d969432f.pdf",
            "news_date": "2024-05-03 16:00:25",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2024",
            "news_body": "Audited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Financial Year Ended On 31 March 2024.",
            "news_id": "0deff1fa-ab93-42ee-87fc-c29302fd92e7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a57bfa99-d5fc-473b-a556-17d6d5d363ca.pdf",
            "news_date": "2024-05-03 15:41:25",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 20 January 2024 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2023.",
            "news_id": "7836e465-52fc-4d17-9d63-d819d842e51b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8247c09f-eef8-463e-9803-dbc31dc80ba5.pdf",
            "news_date": "2024-01-24 17:28:37",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Nine Months Ended 31 December 2023.",
            "news_id": "08f6a038-1734-4eb4-82d0-0009138f92e9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bfd06438-7391-46a6-85ae-be8325f42f26.pdf",
            "news_date": "2024-01-20 15:33:41",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2023",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended on 31 December 2023",
            "news_id": "733feb59-deec-4084-ad62-516f81fdc78d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a198ff4f-d4ac-4837-915a-b484c47d69ce.pdf",
            "news_date": "2024-01-20 15:26:22",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 02 November 2023 post announcement of financial results of the Company for the quarter and half year ended 30 September 2023",
            "news_id": "84e278f4-9553-4d24-99c6-f6c31611959a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9adf0e68-8c94-4cfe-82c9-75ec6542c85e.pdf",
            "news_date": "2023-11-07 16:53:29",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the Quarter and Half Year ended 30 September 2023.",
            "news_id": "e9c17520-2041-492b-a1d7-fc311dcc3fa9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f75a0c4-9a31-4881-a117-e4529e77326d.pdf",
            "news_date": "2023-11-02 17:06:58",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On 30 September 2023",
            "news_body": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On 30 September 2023<BR>",
            "news_id": "bc231248-3234-4a6d-a0d4-5912432a0ba9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7309991-d90b-46f6-865c-94737ec209b9.pdf",
            "news_date": "2023-11-02 15:57:00",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 02.11.2023",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2023.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 02 November 2023.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 11:45 A.M. and concluded at 03:35 P.M.",
            "news_id": "ba049c1f-7c6e-4940-ba53-c0bd33dae446",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdc956a9-8e90-43bb-b95a-0c3848960f4e.pdf",
            "news_date": "2023-11-02 15:44:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings call held on 04 August 2023 post announcement of financial results of the Company for the quarter ended 30 June 2023",
            "news_id": "ccd2d46d-bc07-465d-892c-88277104e79c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2dbdfe35-ab4c-4aec-b59a-e7b9c2126251.pdf",
            "news_date": "2023-08-09 21:20:56",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for the quarter ended 30 June 2023",
            "news_id": "e452d245-52ae-4bd3-9957-39c4976f8bd2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b5ee3f7-f9ab-480e-b875-6ddb60e26c56.pdf",
            "news_date": "2023-08-04 16:03:38",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On 30 June 2023",
            "news_body": "Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on 30 June 2023",
            "news_id": "adb8e0f4-2c61-46b3-adb5-a54d43d2b5b2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=765fd745-2d21-49e8-99c0-f44a82149aa2.pdf",
            "news_date": "2023-08-04 15:03:06",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 05 May 2023 post announcement of financial results of the Company for the quarter and financial year ended 31 March 2023. The above information shall be made available on Company's website of at www.tatvachintan.com.",
            "news_id": "8c1b10fa-ad86-428f-9598-c0a691747adc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8bed5ca3-58fc-4a6e-85f8-761550cdad03.pdf",
            "news_date": "2023-05-10 14:52:20",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and financial year ended 31 March 2023.\u00a0The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "ad1ec11e-4e47-4c30-a185-0d562daf6c41",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d81047d8-a458-439b-9066-eef4973f5564.pdf",
            "news_date": "2023-05-05 16:49:37",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2023",
            "news_body": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter and Financial Year Ended On 31 March 2023",
            "news_id": "2f76a89f-5736-4341-866e-3e5d3e53329c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19529b9a-fa9e-4c18-b1ee-c3bb8547b01a.pdf",
            "news_date": "2023-05-05 15:55:16",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 05.05.2023",
            "news_body": "Outcome Of The Board Meeting Held On 05.05.2023",
            "news_id": "7e479c9b-14c9-4d6c-a738-14b3928e5745",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e1ab9b9-5ce5-4e2f-bb52-dabfc286e4e3.pdf",
            "news_date": "2023-05-05 15:49:24",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 24 January 2023 post announcement of financial results of the Company for the quarter and nine months ended 31 December 2022. The above information shall be made available on Company's website of at www.tatvachintan.com.",
            "news_id": "de6b83d4-8313-4ff6-a173-6815f5ba874f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=778a6786-8c6b-439a-951e-92e9c5eccb62.pdf",
            "news_date": "2023-01-30 17:02:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and nine months ended 31 December 2022.\u00a0The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "5887a07a-cc7d-4658-b19f-c6e693fa0819",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7627a661-9783-4a5e-a335-14bb566354fa.pdf",
            "news_date": "2023-01-24 16:14:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.",
            "news_id": "f6caa8ec-c50d-489b-9974-3fd6122510e1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec3ed94b-abe9-4760-8c8a-8d92ab043776.pdf",
            "news_date": "2023-01-24 15:52:57",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 24.01.2023",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M.",
            "news_id": "4c091ef3-1f5f-47f7-a9e2-37866e0ef9f1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df7880a2-d953-436b-a6da-39037553ef30.pdf",
            "news_date": "2023-01-24 15:48:37",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.",
            "news_body": "In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions in the format specified under SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22 November 2021, for the half year ended 30 September 2022.The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "e2779910-4634-4c1c-aeb7-a2e4759fae83",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c6c74422-dcdc-4a18-b04b-3bf8c1c4fa47.pdf",
            "news_date": "2022-11-16 16:33:17",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 04 November 2022 post announcement of financial results of the Company for the quarter and half year ended 30 September 2022. The above information shall be made available on Company's website of at www.tatvachintan.com.",
            "news_id": "9eb5a5b8-062a-4c9d-bb75-8891ad1efd69",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d31c2b9-d5c8-44ee-b339-70b029d930f5.pdf",
            "news_date": "2022-11-08 14:19:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and half year ended 30 September 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com.",
            "news_id": "4d38f0ab-a49f-472e-bbab-3255c01f2a99",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c70c60d-6d10-41c5-a7b7-171cdd56b3f9.pdf",
            "news_date": "2022-11-04 16:38:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On 30 September 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 November 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 01:00 P.M. and concluded at 03:55 P.M.",
            "news_id": "76f102fe-f159-4337-b343-38b9867ba763",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=999953e3-9cdf-439c-b462-f4e0fd59f3e0.pdf",
            "news_date": "2022-11-04 16:15:07",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 04.11.2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 November 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 01:00 P.M. and concluded at 03:55 P.M.",
            "news_id": "794b3eee-730f-4ae5-9389-ccd43a212c57",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=939977ad-7cc2-45bb-a11c-7532aacf54c6.pdf",
            "news_date": "2022-11-04 16:10:52",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 July 2022 post announcement of financial results of the Company for the quarter ended 30 June 2022. The above information shall be made available on Company's website of at www.tatvachintan.com.This is for your information and records.",
            "news_id": "71fc1c22-3bd9-4f56-83f3-010644a07fbe",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae5fe1c9-9758-4553-b576-f3bfcedf249e.pdf",
            "news_date": "2022-07-29 11:34:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter ended 30 June 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com.This is for your information and records.",
            "news_id": "99cc4a3c-51a4-4271-b6f7-ee61942258d1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5605c8a3-6517-4977-b734-c11ac57ad8bd.pdf",
            "news_date": "2022-07-25 16:23:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On 30 June 2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M. <BR> <BR> Kindly take above intimation on your record and oblige.",
            "news_id": "f2e69554-0caa-4f39-a2a5-e79f9b2d30de",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e76545e-8e4f-420b-808a-9fb50a48f42a.pdf",
            "news_date": "2022-07-25 15:44:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 25.07.2022",
            "news_body": "Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022.<BR> <BR> The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022.<BR> <BR> Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations.<BR> <BR> The above information shall be made available on the website of the Company at www.tatvachintan.com.<BR> <BR> The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M. <BR> <BR> Kindly take above intimation on your record and oblige.",
            "news_id": "25e1dd8b-1d85-43c7-a205-734179ccebd3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db1966d5-8e87-4ea5-b76c-a039689f9dc8.pdf",
            "news_date": "2022-07-25 15:40:47",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.",
            "news_body": "Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half year ended 31 March 2022.The above information shall be uploaded on the website of the Company at www.tatvachintan.com.Kindly take the same on your record.",
            "news_id": "333d7c8b-0b6c-4f37-82b6-f5dd241c29d7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9f80ff4-3bd3-401f-ad12-0280af1a89dc.pdf",
            "news_date": "2022-05-20 16:58:51",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on  25 April 2022 post announcement of financial results of the Company for the quarter and year ended 31 March 2022. The above information will also be hosted on Company's website of at www.tatvachintan.com.This is for your information and records.",
            "news_id": "06946ec3-b5f0-4b94-8bf3-24fbd954bad8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7af8b2e-0e1d-4331-bb1d-5d8a778daf7e.pdf",
            "news_date": "2022-04-28 17:22:58",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at www.tatvachintan.com.This is for your information and records.",
            "news_id": "51bd7be7-30e8-46d8-a179-ddb97c86851c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e0bbe9f-a9f7-465d-b13e-7fffda449cca.pdf",
            "news_date": "2022-04-25 19:31:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Year Ended On 31 March 2022",
            "news_body": "Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on 31 March 2022",
            "news_id": "caf4ff66-1a7a-4232-8837-c44d99319eb7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f117c854-a8b0-48cb-a384-b54acfe7b71b.pdf",
            "news_date": "2022-04-25 15:46:49",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 25.04.2022",
            "news_body": "Outcome Of The Board Meeting Held On 25.04.2022",
            "news_id": "fdc5a97e-36dc-49b5-a1e9-f464dd98c84a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3420afc4-19a9-4e15-938c-1d8fa011b5d5.pdf",
            "news_date": "2022-04-25 15:43:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on January 18, 2022 post announcement of financial results of the Company for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company''s website.This is for your information and records.",
            "news_id": "b038763c-6089-463c-981f-e130c105a50b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=975018b0-1235-4b89-9a50-17b436c86bde.pdf",
            "news_date": "2022-01-22 16:18:13",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "We hereby enclosed Investor Presentation for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company's website.<BR> <BR> This is for your information and records.",
            "news_id": "c3e0a3a2-df8f-4dfa-9b07-12c924527372",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12007f95-3267-4ee1-a8fa-4cdb280c1890.pdf",
            "news_date": "2022-01-18 18:59:36",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financials Results For The Quarter And Nine Months Ended December 31, 2021",
            "news_body": "Unaudited Financials Results For The Quarter And Nine Months Ended December 31, 2021",
            "news_id": "39921e88-e714-4d2a-a71b-fe6479b19508",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28f6c539-c2a4-4a7c-a313-f3a761e2a092.pdf",
            "news_date": "2022-01-17 17:40:13",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On January 17, 2022",
            "news_body": "Outcome of the Board Meeting held on January 17, 2022",
            "news_id": "7622f4da-0749-49b3-b698-bd0169e421c1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87ad0c18-ed67-46d9-addf-3f4a0064a613.pdf",
            "news_date": "2022-01-17 17:31:26",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015<BR> as amended, please find enclosed herewith the transcript of the earnings call held on 25 October 2021<BR> post announcement of financial results of the Company for the quarter and half year ended 30 September<BR> 2021. The Transcript has been uploaded on the Company's website www.tatvachintan.com.<BR> This is for your information and records.",
            "news_id": "e11bf1fc-c503-4ce5-b6e9-a4889a0bad6f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69abab09-4d33-4734-b55f-df16ff8b1b68.pdf",
            "news_date": "2021-10-29 18:05:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Consolidated And Standalone Financial Results For The Quarter And Half Year Ended 30 September 2021.",
            "news_body": "We are enclosing herewith, the un-audited consolidated and standalone financial results of the Company along with limited review report for the quarter and half year ended 30 September 2021, which have been approved and taken on record at a meeting of the Board of Directors of the Company held today.<BR> The above information is also available on the website of the Company: www.tatvachintan.com",
            "news_id": "fa63175e-f3dd-4a17-935d-aec26cf20438",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ca3ce35-312f-4a93-8b30-3402ee7889f9.pdf",
            "news_date": "2021-10-23 15:12:38",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 23 October 2021",
            "news_body": "We wish to inform that the Board of Directors of the Company at its meeting held today i.e., 23 October 2021, has approved the unaudited financial results of the Company (both standalone and consolidated) prepared in accordance with Indian Accounting Standards (IndAS) for the quarter and half year ended as on 30 September 2021. <BR> A copy of the said Financial Results together with Limited review report are enclosed herewith. <BR> The Board meeting commenced at 11.30 am and concluded at 3.00 pm.",
            "news_id": "e5fde7b3-5ce9-45a9-ba71-8256dfa7e8c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70ea360e-021f-4dc6-8e64-91886583ec83.pdf",
            "news_date": "2021-10-23 15:07:58",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "The transcript of the earnings call held on 16 August 2021 post<BR> announcement of financial results of the company for the quarter ended 30 June 2021 .",
            "news_id": "06864f89-ea7e-47bb-9067-35219dc9755e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=701348c6-ccaf-45c1-b4b3-11902caff13c.pdf",
            "news_date": "2021-09-01 17:51:06",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Submission Of Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended 30Th June, 2021",
            "news_body": "Submission of Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter ended 30th June, 2021",
            "news_id": "4164565d-f8a7-435c-8b4d-6d599f3334c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdf65d6c-cae2-4d9d-9cf4-525d40e1484a.pdf",
            "news_date": "2021-08-14 17:47:39",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th August, 2021 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "1. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Consolidated Financial Results;<BR> 2. Copy of the Un-audited Consolidated Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR> 3. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Standalone Financial Results;<BR> 4. Copy of the Un-audited Standalone Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR>",
            "news_id": "91f3bb56-e225-4f92-b8a3-50134c05ef68",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cdb57fab-2b27-4e6b-a720-9e8894172d2f.pdf",
            "news_date": "2021-08-14 17:43:47",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "TATVA",
            "disp": "Tatva Chintan Pharma",
            "bse_code": 543321,
            "isin": "INE0GK401011",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th August, 2021 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "1. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Consolidated Financial Results;<BR> 2. Copy of the Un-audited Consolidated Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR> 3. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Standalone Financial Results;<BR> 4. Copy of the Un-audited Standalone Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;<BR>",
            "news_id": "ef30fac1-4912-4868-b559-f5df3e4692c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec5eda8f-4305-41fc-a91d-cfc8ec475fe3.pdf",
            "news_date": "2021-08-14 17:43:04",
            "seo": "tatva-chintan-pharma-ltd",
            "ltp": 1182.9,
            "ch": -12.399999999999864,
            "pch": -1.0373964695055522,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 5162,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}